CA3143027A1 - Novel secreted antigens for diagnosis of active babesia microti and babesia duncani infection in humans and animals - Google Patents

Novel secreted antigens for diagnosis of active babesia microti and babesia duncani infection in humans and animals Download PDF

Info

Publication number
CA3143027A1
CA3143027A1 CA3143027A CA3143027A CA3143027A1 CA 3143027 A1 CA3143027 A1 CA 3143027A1 CA 3143027 A CA3143027 A CA 3143027A CA 3143027 A CA3143027 A CA 3143027A CA 3143027 A1 CA3143027 A1 CA 3143027A1
Authority
CA
Canada
Prior art keywords
infection
babesia
subject
sample
microti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3143027A
Other languages
English (en)
French (fr)
Inventor
Choukri BEN MAMOUN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CA3143027A1 publication Critical patent/CA3143027A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3143027A 2019-06-12 2020-06-12 Novel secreted antigens for diagnosis of active babesia microti and babesia duncani infection in humans and animals Pending CA3143027A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962860662P 2019-06-12 2019-06-12
US62/860,662 2019-06-12
US201962937645P 2019-11-19 2019-11-19
US62/937,645 2019-11-19
PCT/US2020/037500 WO2020252313A1 (en) 2019-06-12 2020-06-12 Novel secreted antigens for diagnosis of active babesia microti and babesia duncani infection in humans and animals

Publications (1)

Publication Number Publication Date
CA3143027A1 true CA3143027A1 (en) 2020-12-17

Family

ID=73781883

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3143027A Pending CA3143027A1 (en) 2019-06-12 2020-06-12 Novel secreted antigens for diagnosis of active babesia microti and babesia duncani infection in humans and animals

Country Status (8)

Country Link
US (1) US20220236268A1 (https=)
EP (1) EP3983430A4 (https=)
JP (2) JP2022536679A (https=)
CN (1) CN114072419A (https=)
AU (1) AU2020292378A1 (https=)
BR (1) BR112021025089A2 (https=)
CA (1) CA3143027A1 (https=)
WO (1) WO2020252313A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220341928A1 (en) * 2021-04-23 2022-10-27 Id-Fish Technology, Inc. Diagnosis of babesia using babesia recombinant proteins
CN119462946B (zh) * 2024-10-21 2025-10-03 华中农业大学 抗邓肯巴贝斯虫ald蛋白的单克隆抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053016A2 (en) * 2001-01-05 2002-07-11 Corixa Corporation Compounds and methods for the diagnosis and treatment of babesia infection
US7704508B2 (en) * 2007-09-14 2010-04-27 New York Blood Center Babesia subtilisin
CN104845981B (zh) * 2015-05-25 2018-06-19 中国疾病预防控制中心寄生虫病预防控制所 田鼠巴贝虫Bm1524抗原及其应用
US20180372742A1 (en) * 2015-12-10 2018-12-27 Immport Therapeutics, Inc. Babesia Biomarkers for Diagnostic and Screening In Vitro Diagnostic Test
CN108893476B (zh) * 2018-06-28 2022-07-05 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) 田鼠巴贝虫2d97抗原蛋白及其应用

Also Published As

Publication number Publication date
AU2020292378A1 (en) 2022-01-06
JP2025186283A (ja) 2025-12-23
EP3983430A4 (en) 2023-10-11
JP2022536679A (ja) 2022-08-18
EP3983430A1 (en) 2022-04-20
WO2020252313A1 (en) 2020-12-17
US20220236268A1 (en) 2022-07-28
BR112021025089A2 (pt) 2022-02-15
CN114072419A (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
KR102570713B1 (ko) SARS-CoV-2 감염의 진단을 위한 방법 및 시약
Chan et al. Plasmodium vivax Reticulocyte Binding Proteins for invasion into reticulocytes
Proellocks et al. A lysine‐rich membrane‐associated PHISTb protein involved in alteration of the cytoadhesive properties of Plasmodium falciparum‐infected red blood cells
Buchholz et al. Bradyzoite pseudokinase 1 is crucial for efficient oral infectivity of the Toxoplasma gondii tissue cyst
JP4538464B2 (ja) 視神経脊髄炎用マーカー
AU2008221383B2 (en) Brachyury polypeptides and methods for use
Ito et al. RALP1 is a rhoptry neck erythrocyte-binding protein of Plasmodium falciparum merozoites and a potential blood-stage vaccine candidate antigen
JP2025186283A (ja) ヒトおよび動物における活動性のバベシア・ミクロティ感染およびバベシア・ダンカニ感染を診断するための新規な分泌抗原
Hermand et al. Plasmodium falciparum proteins involved in cytoadherence of infected erythrocytes to chemokine CX3CL1
Peng et al. Breadth of humoral response and antigenic targets of sporozoite‐inhibitory antibodies associated with sterile protection induced by controlled human malaria infection
Li et al. Recombinant antigens for immunodiagnosis of cystic echinococcosis
KR20170122262A (ko) 특히 바큘로바이러스-발현 아단위 항원을 위한 마커 시스템
HUP0200777A2 (en) Method of diagnosing transmissible spongiform encephalopathies
Bertuccini et al. Unveiling Cryptosporidium parvum sporozoite-derived extracellular vesicles: profiling, origin, and protein composition
Nagaoka et al. The N-terminal region of Plasmodium falciparum MSP10 is a target of protective antibodies in malaria and is important for PfGAMA/PfMSP10 interaction
de Moraes et al. Murine model for preclinical studies of Var2CSA-mediated pathology associated with malaria in pregnancy
US20140341931A1 (en) Soluble cd27 (scd27) and the use thereof
JP2026034816A (ja) 潜伏形態のトキソプラズマ症についての新たな血清マーカー
DK2646462T3 (en) METHODS AND COMPOSITIONS FOR MONITORING PHAGOCYTIC ACTIVITY
WO2013092793A1 (en) Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions
CN103491979A (zh) 基于来自恶性疟原虫的红细胞前期抗原的疟疾疫苗
Pitabut et al. IgG antibody profile to c-terminal region of Plasmodium vivax merozoite surface protein-1 in Thai individuals exposed to malaria
Brose et al. Virulent African swine fever virus infection of porcine monocytes causes SLA I subversion due to loss of proper ER structure/function
Sharada et al. Expression of glycoprotein gene of Rabies virus and evaluation of recombinant protein for seromonitoring of vaccinal antibodies in dogs
Tuvshintulga et al. Disruption of a DNA fragment that encodes the microneme adhesive repeat domain-containing region of the BBOV_III011730 does not affect the blood stage growth of Babesia bovis in vitro

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240508

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250606

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250606

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250917

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260211